These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 28417535

  • 21. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
    Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R, NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators.
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
    [Abstract] [Full Text] [Related]

  • 22. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
    Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB.
    Diabetes Obes Metab; 2015 Oct; 17(10):965-73. PubMed ID: 25980900
    [Abstract] [Full Text] [Related]

  • 23. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM.
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [Abstract] [Full Text] [Related]

  • 24. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
    Janez A, Őrsy P, Stachlewska K, Salvesen-Sykes K, Billings LK, Philis-Tsimikas A.
    Diabetes Obes Metab; 2020 Apr; 22(4):658-668. PubMed ID: 31858673
    [Abstract] [Full Text] [Related]

  • 25. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT, Xu H, Wagner R.
    Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
    [Abstract] [Full Text] [Related]

  • 26. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M, Mocarski M, Langer J, Hunt B.
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I, Pérez Manghi F, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB, DUAL V Investigators.
    JAMA; 2016 Mar 01; 315(9):898-907. PubMed ID: 26934259
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.
    Kumar S, Jang HC, Demirağ NG, Skjøth TV, Endahl L, Bode B.
    Diabet Med; 2017 Feb 01; 34(2):180-188. PubMed ID: 27027878
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM.
    Diabetes Care; 2013 Sep 01; 36(9):2536-42. PubMed ID: 23715753
    [Abstract] [Full Text] [Related]

  • 35. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
    Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Raskin P, Zacho J, Andersen TH, Philis-Tsimikas A.
    Diabetes Obes Metab; 2016 Jul 01; 18(7):663-70. PubMed ID: 26990378
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.